TEVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Teva Pharmaceutical Industries's retained earnings for the quarter that ended in Mar. 2024 was $-13,673 Mil.
Teva Pharmaceutical Industries's quarterly retained earnings increased from Sep. 2023 ($-13,870 Mil) to Dec. 2023 ($-13,534 Mil) but then declined from Dec. 2023 ($-13,534 Mil) to Mar. 2024 ($-13,673 Mil).
Teva Pharmaceutical Industries's annual retained earnings declined from Dec. 2021 ($-10,529 Mil) to Dec. 2022 ($-12,975 Mil) and declined from Dec. 2022 ($-12,975 Mil) to Dec. 2023 ($-13,534 Mil).
The historical data trend for Teva Pharmaceutical Industries's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Retained Earnings | Get a 7-Day Free Trial | -6,956.00 | -10,946.00 | -10,529.00 | -12,975.00 | -13,534.00 |
Teva Pharmaceutical Industries Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Retained Earnings | Get a 7-Day Free Trial | -13,086.00 | -13,950.00 | -13,870.00 | -13,534.00 | -13,673.00 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Teva Pharmaceutical Industries (NYSE:TEVA) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Dov Bergwerk | officer: Acting Chief Legal Officer | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Vikki L Conway | officer: See "Remarks" | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Varda Shalev | director | MATAM PARK, BUILDING #5, HAIFA L3 3508409 |
Eliyahu Sharon Kalif | officer: EVP, Chief Financial Officer | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Amir Weiss | officer: Chief Accounting Officer | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Angus Grant | officer: EVP, Business Development | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Eric A Hughes | officer: See "Remarks" | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Sven Dethlefs | officer: EVP Global Marketing&Portfolio | 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Eric Drape | officer: Executive VP Global Operations | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
David Matthew Stark | officer: Exec. VP Chief Legal Officer | 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Richard Daniell | officer: Exec. VP, European Commercial | 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033 |
Richard D Francis | officer: President and CEO | IM LANGACHER 44, GREIFENSEE V8 8606 |
Hafrun Fridriksdottir | officer: Executive VP, Global R&D | 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Eli Shani | officer: EVP,Global Marketing&Portfolio | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Tal Zvi Zaks | director | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
From GuruFocus
By Business Wire • 10-04-2023
By Business Wire • 07-05-2023
By Business Wire • 09-06-2023
By GuruFocus Research • 09-20-2023
By Business Wire • 01-02-2024
By Nathan Aisenstadt • 11-21-2023
By Business Wire Business Wire • 06-12-2023
By Business Wire • 11-20-2023
By Business Wire • 08-21-2023
By Business Wire • 11-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.